Women’s cardiovascular health is shaped by unique risks, from hormonal changes to the impact of cancer treatments. Proactive monitoring and personalized care are essential. InfoBionic.Ai’s MoMe ARC® delivers real-time cardiac insights, empowering physicians to improve patient outcomes.

BOSTON, Feb. 25, 2025 /PRNewswire-PRWeb/ — A recent study published in the Journal of the American Medical Association (JAMA) suggests a link between cardiovascular disease (CVD) and breast cancer. The case-control study found that women with cardiovascular disease were more likely to be diagnosed with advanced-stage breast cancer, specifically hormone receptor-positive, ERBB2-negative (formerly HER2-negative) subtypes. (1) “While these findings are still in their early stages, the emerging connection between cardiovascular disease and breast cancer underscores the critical need for early detection and continuous heart health monitoring—especially during pivotal hormonal transitions such as menopause,” explains Anna Norman, Vice President of Product for InfoBionic.Ai. “Although researchers are still investigating the exact mechanisms behind this link, the evidence reinforces the necessity of a more integrated approach to women’s healthcare.”

Gender Differences in Heart Disease Symptoms and Treatment

Despite heart disease being the leading cause of death among both men and women, there are stark differences in how it presents and is treated. Women often experience atypical heart attack symptoms, such as nausea, fatigue, and jaw pain, leading to delays in diagnosis and treatment. Studies indicate that biological factors, including sex hormones, contribute to differences in cardiovascular disease prevalence and severity between men and women. (2)
Additionally, research suggests that heart attack diagnoses are missed more frequently in women than in men. (3) These disparities reinforce the need for gender-specific approaches to cardiovascular care and patient education.

The Role of Hormones in Women’s Cardiovascular Health

Hormonal fluctuations, particularly the decline in estrogen levels during menopause, play a critical role in cardiovascular health. Estrogen provides a protective effect on blood vessels, and its loss increases the risk of hypertension, atherosclerosis, and other cardiovascular conditions. Research from the Mayo Clinic explains how declining estrogen levels contribute to arterial plaque buildup, raising the likelihood of heart attacks and strokes in postmenopausal women. (4) Additionally, findings from the Swedish Nationwide Register suggest that outcomes of hormone replacement therapy (HRT) vary depending on the timing and type of therapy used. (5)
A study using NHANES data from 1999–2020 further reinforces the connection, showing a significant association between female hormone intake and cardiovascular disease risk. (6) These findings stress the need for personalized medical interventions to mitigate cardiovascular risks in women undergoing hormonal changes

Breast Cancer Treatment and Long-Term Cardiovascular Risk

While the connection between pre-existing CVD and advanced breast cancer is gaining attention, research also highlights the long-term cardiovascular risks faced by breast cancer survivors. A study published in The Journal of Clinical Oncology found that breast cancer patients treated with anthracyclines and trastuzumab—a common chemotherapy regimen—had an increased risk of heart failure and other cardiovascular complications. (7)

Furthermore, The Impact of Cardiovascular Disease on All-Cause and Cancer Mortality, a 16-year follow-up study from Germany, found that breast cancer patients with CVD had significantly higher mortality rates, reinforcing the need for integrated cancer and cardiovascular care. (8)

The Path Forward: Integrating Women’s Heart and Cancer Care
As research continues to reveal the intricate connections between various health conditions, it is imperative that healthcare providers adopt a more integrated approach to women’s health. This includes:

  • Proactive cardiovascular screening for women, particularly those undergoing breast cancer treatment or experiencing menopause.
  • Personalized hormone therapy strategies that consider cardiovascular risks and benefits.
  • Education on heart attack symptoms in women to promote early detection and intervention.
  • Advanced cardiac monitoring technologies to provide continuous insights into heart health.

Advancing Women’s Cardiovascular Care with Continuous Monitoring

As awareness grows around women’s unique cardiovascular risks, the healthcare industry is developing more advanced monitoring tools to improve patient care. Continuous cardiac monitoring can play a pivotal role in identifying irregular heart activity, allowing for early intervention and better patient outcomes.

InfoBionic.Ai’s MoMe ARC® platform is a remote cardiac monitoring solution designed to support physicians in evaluating heart health by providing continuous ECG data. Once prescribed by a doctor, MoMe ARC® helps identify cardiac abnormalities in patients already experiencing symptoms, offering clinicians valuable insights into cardiovascular conditions. While the platform does not play a role in early detection, it enhances patient care by enabling real-time monitoring, which is particularly relevant for women managing cardiovascular risks associated with hormonal changes or a history of breast cancer.

“The ability to continuously monitor cardiovascular health is a game-changer in proactive women’s healthcare,” Norman emphasis. “While no single solution can eliminate risk, combining advanced monitoring technology with comprehensive medical care enables clinicians to make timely and informed decisions that can ultimately save lives.”

About InfoBionic.Ai

InfoBionic.Ai’s digital technology has transformed the efficiency and economics of cardiac remote patient monitoring. The company’s vision for its FDA-cleared third-generation platform, the MoMe ARC®, is to remove the roadblocks hindering virtual and remote diagnosis and decision-making. The Massachusetts-based team of seasoned entrepreneurs has had successful careers in healthcare, IT, medical devices, and mobile technology, and brings specific expertise in remote monitoring and cardiology. Visit https://infobionic.ai

References

1.    Angelov, Ivan, et al. “Cardiovascular Disease and Breast Cancer Stage at Diagnosis.” JAMA, 2 Jan. 2025, jamanetwork.com/journals/jamanetworkopen/fullarticle/2828637.
2.    Regitz-Zagrosek, Vera, and Catherine Gebhard. “Gender Medicine: Effects of Sex and Gender on Cardiovascular Disease Manifestation and Outcomes.” Nature Reviews Cardiology, vol. 20, 31 Oct. 2022,doi.org/10.1038/s41569-022-00797-4.
3.    Antipolis, Sophia. “Heart Attack Diagnosis Missed in Women More Often than in Men.” escardio.org, 12 Mar. 2021, escardio.org/The-ESC/Press-Office/Press-releases/Heart-attack-diagnosis-missed-in-women-more-often-than-in-men
4.    Williams, Vivien. “Mayo Clinic Minute: Women, Estrogen and Heart Disease.” Mayo Clinic, Mayo Foundation for Medical Education and Research, 18 Mar. 2022, newsnetwork.mayoclinic.org/discussion/mayo-clinic-minute-women-estrogen-and-heart-disease/#:~:text=Men%20and%20women%20have%20an,of%20estrogen%20as%20the%20cause
5.    Johansson, Therese, et al. “Contemporary Menopausal Hormone Therapy and Risk of Cardiovascular Disease: Swedish Nationwide Register Based Emulated Target Trial.” The BMJ, British Medical Journal Publishing Group, 27 Nov. 2024, bmj.com/content/387/bmj-2023-078784
6.    Qu, Shenao, et al. “Association between the Female Hormone Intake and Cardiovascular Disease in the Women: A Study Based on Nhanes 1999–2020 – BMC Public Health.” BioMed Central, BioMed Central, 24 Dec. 2024, bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-024-21001-x
7.    Greenlee, Heather, et al. “Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study.” Journal of Clinical Oncology, ASCO, 6 Apr. 2022, ascopubs.org/doi/10.1200/JCO.21.01736.
8.    Möhl, Annika, et al. “The Impact of Cardiovascular Disease on All-Cause and Cancer Mortality: Results from a 16-Year Follow-up of a German Breast Cancer Case–Control Study – Breast Cancer Research.” BioMed Central, BioMed Central, 27 July 2023, breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-023-01680-x

Media Inquiries:
Karla Jo Helms
JOTO PR™
727-777-4629
jotopr.com